Repligen Corporation (RGEN) — Fair Value Analysis

Base-case fair value (P50): $99.79 · Current price: $125.69 · Verdict: Overvalued

The Verdict on RGEN

Based on our proprietary Monte Carlo simulations, REPLIGEN CORP (RGEN) appears Overvalued at its current market price of $125.69. Our analysis, which models thousands of forward-looking scenarios to assess intrinsic value, indicates a median fair value (P50) for RGEN at $99.79. This implies a significant -20.6% difference compared to the current trading level, suggesting the stock is trading above its fundamental valuation. For investors seeking value, this disparity highlights a potential overextension in RGEN's price relative to its underlying financial health and growth prospects.

How RGEN stacks up against peers

While RGEN operates within a dynamic sector, its operational and financial health is currently assessed as average compared to its peers. This average quality tier suggests the company maintains a stable, but not exceptional, competitive position. Despite this, the market's enthusiasm has pushed RGEN's share price to $125.69, noticeably higher than our calculated P50 fair value of $99.79. This valuation gap, reflected in the -20.6% figure, underscores a disconnect where market sentiment may be outstripping the company's intrinsic worth when benchmarked against industry performance.

What this means for investors

The Monte Carlo simulation points to RGEN being Overvalued, with the stock trading at $125.69 against a median fair value of $99.79. This implies a substantial -20.6% downside scenario if the stock converges to its intrinsic value. Given RGEN's average quality tier, investors should carefully consider the risks associated with the current premium valuation. Our FairCurve analysis suggests caution for those initiating new positions at these levels. To explore the full bear-case (P10) and bull-case (P90) distributions and track RGEN's fair value as new fundamentals are released, sign up for a FairCurve account.